Enoxacin

CHEMBL826 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
320.3 g/mol
LogP
-0.2
Phase
4

This fluoroquinolone antibiotic kills bacteria by blocking enzymes they need to copy and repair their genetic material. It is used to treat certain bacterial infections of the urinary tract and other sites.

Moleküler Ağırlık

320,3200 g/mol

LogP

-0,20

TPSA

85,80 Ų

Lipinski RO5

Geçer

Etki Mekanizması

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21

InChI

InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)

Molecular Formula

C15H17FN4O3

HBD / HBA

2 / 8

Döndürülebilir Bağlar

3

Ağır Atomlar

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This fluoroquinolone antibiotic kills bacteria by blocking enzymes they need to copy and repair their genetic material. It is used to treat certain bacterial infections of the urinary tract and other sites.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Enoxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL826. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3229. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.